primary antibody against sparc  (Thermo Fisher)

Journal: Oncology Letters

Article Title: Clinical significance of secreted protein, acidic and cysteine-rich gene expression in patients with stage II/III gastric cancer following curative resection and adjuvant chemotherapy with S-1

doi: 10.3892/ol.2018.8248

Figure Lengend Snippet: Expression of SPARC was evaluated by immunohistochemical analysis of resected gastric cancer specimens. Positive staining for SPARC was observed in stromal cells and cancer cells, but was markedly more intense in stromal cells than in cancer cells. (A) ×200; and (B) ×400. SPARC, secreted protein, acidic and cysteine-rich.

Article Snippet: Primary polyclonal antibodies against SPARC (dilution, 1:50; cat. no. sc-25574; Santa Cruz Biotechnology, Inc., Dallas, TX, USA).

Techniques: Expressing, Immunohistochemical staining, Staining

Journal: Oncology Letters

Article Title: Clinical significance of secreted protein, acidic and cysteine-rich gene expression in patients with stage II/III gastric cancer following curative resection and adjuvant chemotherapy with S-1

doi: 10.3892/ol.2018.8248

Figure Lengend Snippet: SPARC and β-actin mRNA expression in (A) 7 gastric cancer cell lines and (B) clinical samples, as determined by reverse-transcription polymerase chain reaction. The product size of SPARC and β-actin was 126 and 171 base pairs, respectively. SPARC, secreted protein, acidic and cysteine-rich; p, positive control; n, negative control; T, tumor; N, adjacent normal mucosa.

Article Snippet: Primary polyclonal antibodies against SPARC (dilution, 1:50; cat. no. sc-25574; Santa Cruz Biotechnology, Inc., Dallas, TX, USA).

Techniques: Expressing, Reverse Transcription, Polymerase Chain Reaction, Positive Control, Negative Control

Journal: Oncology Letters

Article Title: Clinical significance of secreted protein, acidic and cysteine-rich gene expression in patients with stage II/III gastric cancer following curative resection and adjuvant chemotherapy with S-1

doi: 10.3892/ol.2018.8248

Figure Lengend Snippet: Comparison of SPARC expression levels between gastric cancer tissues and adjacent normal mucosa (P=0.0012, as determined using the Wilcoxon's signed rank test). Box indicates the interquartile range (25–75%), the horizontal line indicates the mean and the bars indicates the first and ninth decile. SPARC, secreted protein, acidic and cysteine-rich.

Article Snippet: Primary polyclonal antibodies against SPARC (dilution, 1:50; cat. no. sc-25574; Santa Cruz Biotechnology, Inc., Dallas, TX, USA).

Techniques: Comparison, Expressing

Journal: Oncology Letters

Article Title: Clinical significance of secreted protein, acidic and cysteine-rich gene expression in patients with stage II/III gastric cancer following curative resection and adjuvant chemotherapy with S-1

doi: 10.3892/ol.2018.8248

Figure Lengend Snippet: Univariate analysis of potential prognostic variables for overall survival.

Article Snippet: Primary polyclonal antibodies against SPARC (dilution, 1:50; cat. no. sc-25574; Santa Cruz Biotechnology, Inc., Dallas, TX, USA).

Techniques: Expressing

Journal: Oncology Letters

Article Title: Clinical significance of secreted protein, acidic and cysteine-rich gene expression in patients with stage II/III gastric cancer following curative resection and adjuvant chemotherapy with S-1

doi: 10.3892/ol.2018.8248

Figure Lengend Snippet: Multivariate analysis of potential prognostic variables for overall survival.

Article Snippet: Primary polyclonal antibodies against SPARC (dilution, 1:50; cat. no. sc-25574; Santa Cruz Biotechnology, Inc., Dallas, TX, USA).

Techniques: Expressing

Journal: Oncology Letters

Article Title: Clinical significance of secreted protein, acidic and cysteine-rich gene expression in patients with stage II/III gastric cancer following curative resection and adjuvant chemotherapy with S-1

doi: 10.3892/ol.2018.8248

Figure Lengend Snippet: Association between SPARC gene expression and potential prognostic variables.

Article Snippet: Primary polyclonal antibodies against SPARC (dilution, 1:50; cat. no. sc-25574; Santa Cruz Biotechnology, Inc., Dallas, TX, USA).

Techniques: Gene Expression, Expressing

Journal: Oncology Letters

Article Title: Clinical significance of secreted protein, acidic and cysteine-rich gene expression in patients with stage II/III gastric cancer following curative resection and adjuvant chemotherapy with S-1

doi: 10.3892/ol.2018.8248

Figure Lengend Snippet: Comparison of overall survival rates between low and high SPARC expression levels in patients who had following adjuvant S-1 chemotherapy (P=0.000006, as determined using the log-rank test). SPARC, secreted protein, acidic and cysteine-rich.

Article Snippet: Primary polyclonal antibodies against SPARC (dilution, 1:50; cat. no. sc-25574; Santa Cruz Biotechnology, Inc., Dallas, TX, USA).

Techniques: Comparison, Expressing, Adjuvant

Journal: Oncology Letters

Article Title: Clinical significance of secreted protein, acidic and cysteine-rich gene expression in patients with stage II/III gastric cancer following curative resection and adjuvant chemotherapy with S-1

doi: 10.3892/ol.2018.8248

Figure Lengend Snippet: Comparison of overall survival rates between high and low SPARC expression levels in patients with stage II gastric cancer who had following adjuvant S-1 chemotherapy (P=0.036, as determined using the log-rank test). SPARC, secreted protein, acidic and cysteine-rich.

Article Snippet: Primary polyclonal antibodies against SPARC (dilution, 1:50; cat. no. sc-25574; Santa Cruz Biotechnology, Inc., Dallas, TX, USA).

Techniques: Comparison, Expressing, Adjuvant

Journal: Oncology Letters

Article Title: Clinical significance of secreted protein, acidic and cysteine-rich gene expression in patients with stage II/III gastric cancer following curative resection and adjuvant chemotherapy with S-1

doi: 10.3892/ol.2018.8248

Figure Lengend Snippet: Comparison of overall survival rates between high and low SPARC expression levels in patients with stage III gastric cancer who had following adjuvant S-1 chemotherapy (P=0.000017, as determined using the log-rank test). SPARC, secreted protein, acidic and cysteine-rich.

Article Snippet: Primary polyclonal antibodies against SPARC (dilution, 1:50; cat. no. sc-25574; Santa Cruz Biotechnology, Inc., Dallas, TX, USA).

Techniques: Comparison, Expressing, Adjuvant

Journal: Oncology Letters

Article Title: Clinical significance of secreted protein, acidic and cysteine-rich gene expression in patients with stage II/III gastric cancer following curative resection and adjuvant chemotherapy with S-1

doi: 10.3892/ol.2018.8248

Figure Lengend Snippet: Comparison of overall survival rates between high and low SPARC expression levels in the patients who had not received adjuvant S-1 chemotherapy (P=0.732, as determined using the log-rank test). SPARC, secreted protein, acidic and cysteine-rich.

Article Snippet: Primary polyclonal antibodies against SPARC (dilution, 1:50; cat. no. sc-25574; Santa Cruz Biotechnology, Inc., Dallas, TX, USA).

Techniques: Comparison, Expressing, Adjuvant

Journal: BMC Cancer

Article Title: Establishment of monoclonal HCC cell lines with organ site-specific tropisms

doi: 10.1186/s12885-015-1692-0

Figure Lengend Snippet: Tropism-related genes in HCC metastasis. a The endogenous mRNA levels of ITGA1, VCAM1, SPARC and ANGPTL4 in monoclonal HCC cells analyzed by Real-time PCR analysis. b The protein levels of ITGA1, VCAM1, SPARC and ANGPTL4 of monoclonal HCC cells quantified by Western blot. GAPDH was included as loading control. Data are presented as mean ± SEM, One-way ANOVA was used

Article Snippet: The slides probed with a primary antibody against VCAM1 (1:200, Epitomics, Burlingame, CA), SPARC (1:200, Epitomics, Burlingame, CA), ANGPTL4 (1:100, Abgent, San Diego, CA) and ITGA1 (1:100, Abgent, San Diego, CA), and then incubated with HRP (horseradish peroxidase) -conjugated IgG (1:500, Invitrogen) and the proteins in situ were visualized with 3, 3’-diaminobenzidine.

Techniques: Real-time Polymerase Chain Reaction, Western Blot, Control

Journal: BMC Cancer

Article Title: Establishment of monoclonal HCC cell lines with organ site-specific tropisms

doi: 10.1186/s12885-015-1692-0

Figure Lengend Snippet: Protein levels of ITGA1, VCAM1, SPARC and ANGPTL4 in xenograft tissues. Representative images ( a , ×100) and Quantitative results ( b ) of ITGA1, VCAM1, SPARC and ANGPTL4 protein levels in primary xenograft tissues using immunohistochemical staining analyses. Data are presented as mean ± SEM, One-way ANOVA was used

Article Snippet: The slides probed with a primary antibody against VCAM1 (1:200, Epitomics, Burlingame, CA), SPARC (1:200, Epitomics, Burlingame, CA), ANGPTL4 (1:100, Abgent, San Diego, CA) and ITGA1 (1:100, Abgent, San Diego, CA), and then incubated with HRP (horseradish peroxidase) -conjugated IgG (1:500, Invitrogen) and the proteins in situ were visualized with 3, 3’-diaminobenzidine.

Techniques: Immunohistochemical staining, Staining